• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Midazolam nasal spray trial meets primary endpoint in patients with seizure clusters

April 27, 2017 By Sarah Faulkner

ProximagenProximagen Ltd. said today that its pivotal Phase III trial of intranasal midazolam met its primary efficacy endpoint as a treatment for patients with seizure clusters. The Cambridge-based company said it plans to begin talks with the FDA for a New Drug Application in the 2nd half of this year based on the trial’s findings.

The company’s USL261 formulation was developed for intranasal delivery in patients who require control of intermittent bouts of heightened seizure activity.

“The primary efficacy results observed in the pivotal phase III clinical trial were both statistically and clinically significant. These findings suggest that midazolam nasal spray could be an effective rescue treatment option for patients and caregivers who live with seizure clusters, subject to FDA review,” president Bill Pullman said in prepared remarks. “This is an exciting development because to-date, rescue treatment options for seizure clusters have been very limited. We look forward to working with the FDA and submitting a New Drug Application for midazolam nasal spray later this year.”

The Artemis1 study examined the efficacy and safety of USL261. Proximagen reported that the drug terminated seizures within 10 minutes after administration and prevented seizure recurrence for as long as 6 hours after administration.

Proximagen’s parent company, Upsher-Smith Laboratories, recently sold its generics biz to Sawai and Proximagen was bought by a newly created holding company, Acova.

“Given the challenges and unmet needs of those living with seizures, we are very encouraged by the results of the Phase III trial of midazolam nasal spray. While there is still work to be done to put this medication into the hands of patients, I’d like to take this opportunity to thank our investigators, along with the teams at Upsher-Smith and Proximagen who have brought us to this major milestone,” Acova CEO Mark Evenstad added. “I am very proud of the important work that Proximagen is doing to help patients and their families by discovering and developing innovative therapies.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological Tagged With: proximagen

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS